Skip to content

Oncolo-Co

Active
Private limited company·Activiteiten van medisch specialisten· 4 yrs active
Besmelaan 103 ·1190 Vorst, Belgium
KBO/BCE: BE 0780.358.961
Watch Print / PDF
Age4 yrs
Connections2

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of Oncolo-Co is 0.4% (very low). The 2024 annual accounts show negative equity (€-4k) and a net result of €1k. Equity is shrinking by ~198.6% per year across the filed fiscal years. Its solvency ranks better than 5% of 6573 sector peers (fiscal year 2024). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 3 annual accounts.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone
0.4% Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector Young company +Higher-failure-rate region +

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Signals

1 signal · with evidence
Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 5% of 6573 sector peers (2024).
View the sector comparison

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Filing behaviour

From the deposit records, complete market-wide
Deadline passed, not yet counted as missing
The deadline for the year that closed on 31-12-2025 passed on 31-07-2026, 12 days ago. Our copy of the deposit register trails the National Bank (measured: median 14 days, p99 45 days), so we only call this filing missing from 45 days past the deadline.
Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 25-08-2025, 25 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
How we compute the deadline
The year end is derived from 3 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2024, that is 31-07-2025.
Deadline per financial year
Year closed Due by Filed Variance Reference
31-12-2025 31-07-2026 nothing on record not filed -
31-12-2024 31-07-2025 25-08-2025 25 d late 2025-00397597
31-12-2023 31-07-2024 09-10-2024 70 d late 2024-00503524
31-12-2022 31-07-2023 01-09-2023 32 d late 2023-00408375

Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Trust signals

2 signals
More than 3 years active
Founded in 2022, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

Financials

Turnover€166k
EBIT margin5.2%
Net result€1k
Working capital€-31k+30.7%

Annual accounts & ratios

Source: NBB · 2024
Annual accounts filed on 25-08-2025 with the NBB · fiscal year 2024 · micro
€-50k€0€50k€100k€150kOperating result 2022: €24k€24kNet result 2022: €15k€15kRevenue 2023: €166k€166kOperating result 2023: €9k€9kNet result 2023: €-23k€-23kOperating result 2024: €52k€52kNet result 2024: €1k€1k202220232024
RevenueOperating resultNet result
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
declining Equity: declining trend of ~198.6%/year over 3 fiscal years, indicative, assuming unchanged policy.
€-40k€-20k€0€20k2025: €-15k (€-16k - €-15k)2026: €-26k (€-27k - €-26k)2027: €-37k (€-38k - €-37k)2022: €18k2023: €-6k2024: €-4k202220232024202520262027
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison
Fiscal year 2024 · NACE 86, Human health · compared within the same schema type (micro schema)
Metric This company Sector median Position in the sector
Solvency -0.3% 66.7%
better than 5% of 6573 sector peers
Net result €1k €46k
better than 10% of 6567 sector peers
Equity €-4k €79k
better than 5% of 6573 sector peers
Gross operating margin €172k €78k
better than 80% of 6575 sector peers
Total assets €1.55M €154k
better than 95% of 6576 sector peers
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
Sector position over time
Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).
Solvency P5
2022: P30 · n=36672023: P5 · n=53292024: P5 · n=65732022 2024
Weakening position over 2022-2024 · n=3667-6573
Net result P10
2022: P27 · n=36652023: P5 · n=53282024: P10 · n=65672022 2024
Weakening position over 2022-2024 · n=3665-6567
Equity P5
2022: P21 · n=36672023: P5 · n=53312024: P5 · n=65732022 2024
Weakening position over 2022-2024 · n=3667-6573
Gross operating margin P80
2022: P27 · n=36632023: P58 · n=53252024: P80 · n=65752022 2024
Improving position over 2022-2024 · n=3663-6575
Describes the position versus peers, not a forecast.
Revenue
€166k
- 22-24
EBITDA
€170k
+120.6% 22-24
Net profit
€1k
- 22-24
Cash flow
€119k
+163.6% 22-24
Total assets
€1.55M
-1.6% 22-24
Equity
€-4k
+20.6% 22-24
Working capital
€-31k
+30.7% 22-24
Staff costs
€0
-100.0% 22-24
Income taxes
€3k
- 22-24
Debt
€1.05M
-1.6% 22-24
Debt ≤ 1y
€66k
-16.4% 22-24
Debt > 1y
€986k
-0.4% 22-24
Current ratio
0.54
+21.7% 22-24
Quick ratio
0.54
+21.7% 22-24
Solvency
-0.3%
+19.3% 22-24
Debt / equity
-239.34
-23.9% 22-24
ROE
-25.9%
- 22-24
ROA
0.1%
- 22-24
Net margin
-13.9%
- 22-24
EBITDA margin
46.4%
- 22-24
Interest coverage
3.60
+48.5% 22-24
Figures by fiscal year
Fiscal year2024
Depositmicro
Revenue-
EBITDA€170k
Net profit€1k
Cash flow€119k
Staff costs-
Income taxes€3k
Dividends-
Total assets€1.55M
Equity€-4k
Debt€1.05M
of which ≤ 1y€66k
of which > 1y€986k
Working capital€-31k
Employees (FTE)-
Ratios (computed)
2024
Current ratio0.54
Quick ratio0.54
Working capital ratio-2.0%
Solvency-0.3%
Debt / equity-239.34
Long-term debt ratio-224.35
Interest coverage3.60
Gross margin-
Net margin-
ROA0.1%
ROE-25.9%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2024
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2024
Balance sheet, Assets
TOTAL ASSETS 20/58€1.55M
Fixed assets 21/28€1.52M
Intangible fixed assets 21€98k
Tangible fixed assets 22/27€1.42M
Current assets 29/58€35k
Amounts receivable within one year 40/41€3k
Cash & bank 54/58€31k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€1.55M
Equity 10/15€-4k
Contributions / capital 10/11€3k
Accumulated profits (losses) 14€-7k
Provisions & deferred taxes 16€507k
Amounts payable 17/49€1.05M
Amounts payable after one year 17€986k
Amounts payable within one year 42/48€66k
Trade debts payable within one year 44€8k
Income statement
Gross operating margin 9900€172k
Operating result 9901€52k
Financial income 75€67
Financial charges 65€47k
Result before taxes 9903€5k
Income taxes 67/77€3k
Net result for the period 9904€1k
Result to be appropriated 9905€1k
You're seeing the latest fiscal year only. Unlock 2 prior years (figures + ratios) with a paid plan. See plans →
Ratios computed by Checked.

Health barometer

FY 2024 · computed
16 / 100 Critical
050100
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.

See plans →
Computed by Checked from the NBB filing for FY 2024. Indicative, not credit advice.

Structure & network

Connections & network

2 connected companies
Network connections
Aspis Aegis
Shared address
PharmaLegal
Shared address
Connections derived from shared directors, addresses, shareholders and group structure in the Belgian State Gazette.

Locations & real estate

Registered office

from the Crossroads Bank
Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Besmelaan 1031190 Vorst

Establishment units

1 location
Oncolo-Co
Lange Gasthuisstraat 13, 2000 AntwerpenActiviteiten van medisch specialisten
since 20222.327.552.513
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels2
Ground area1,103 m²
Buildings2
Building footprint736 m²
Volume (LiDAR)15,132 m³
Tallest building34.1 m · ±10 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 1 (50%) Brussels 1 (50%)
Parcel (capakey) Region Area Buildings Height / fl.
11803C1078/00F000 Flanders 704 m² 1 · 591 m² 34.1 m · 10 fl.
21383B0011/00N005
ProtectedMonumentArt-nouveauhuisSource ↗
Brussels 399 m² 1 · 145 m² 18.9 m · 5 fl.
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
1 of these parcels carry protected heritage (source: regional heritage registers, Onroerend Erfgoed / patrimoine.brussels).

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgisch Staatsblad · acts

3 acts
Capital history · 1
18-09-2025
v3.2
Address history · 1
18-02-2026
v3.2
All acts · 3 updated 5 months ago
2026
18-02-2026 Registered office moved from Antwerpen to Vorst (Brussel) Registered-office change
  • Lange Gasthuisstraat 13, 2000 Antwerpen → Besmelaan 103, 1190 Vorst (Brussel)
Summary: v3.2
2025
18-09-2025 Capital increase of €10,000 Capital & shares
2022
14-01-2022 Incorporation of a new BV Incorporation
Summary: oprichting

Analysis

Snowflake analysis

financial profile on 5 axes
Health16Profitability0Solvency34Growth32Stability94
35 / 100

Fragile profile, watch profitability in particular.

All 5 axes are computed from data Checked has read.

Health 16
Profitability 0
Solvency 34
Growth 32
Stability 94

Ask AI about this company

Checked AI

Soon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.

TryWhat are the main risks?Any recent red flags?Compare to sector peers
Coming soon

AI due-diligence brief

Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon
The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works

Credit advice

verdict per customer and amount

Should this customer buy amount X on invoice? Enter the amount and payment terms, you get an instant GREEN/AMBER/RED verdict, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.

Similar

Similar companies

Comparable size, same sector

Company registry

Company registry (CBE)

Crossroads Bank
Activities
Praktijken van specialisten86220Activiteiten van medisch specialisten86220
Primary activity highlighted.
Names & trade names
Legal nameNL Oncolo-Co
Registered office
Besmelaan 103
1190 Vorst, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.